76813-69-9

Upstream product

• 74469-70-8 2,3-dihydro-2,2-dimethyl-6-hydroxy-4H-1,3-benzoxazin-4-one 
• 52405-73-9 gentisamide 
• 74454-60-7 2,3-dihydro-2,2-dimethyl-6-(2-bromoethoxy)-4H-1,3-benzoxazin-4-one 
• 100-46-9 benzylamine 

Downstream Products

• 79407-04-8 5-(2-{Benzyl-[2-hydroxy-3-(2-methoxy-phenyl)-propyl]-amino}-ethoxy)-2-hydroxy-benzamide 
• 79407-28-6 5-{2-[Benzyl-(2-hydroxy-4-o-tolyl-butyl)-amino]-ethoxy}-2-hydroxy-benzamide 
• 79407-01-5 5-(2-{Benzyl-[2-hydroxy-4-(2-methoxy-phenyl)-butyl]-amino}-ethoxy)-2-hydroxy-benzamide 
• 74454-87-8 5-(2-aminoethoxy) salicylamide 
• 92990-29-9 α-[N-benzyl-N-[2-(3-carbamoyl-4-hydroxy-phenoxy)-ethyl]-aminomethyl]benzyl alcohol 
• 81015-22-7 1-[N-benzyl-[2-(3-carbamoyl-4-hydroxyphenoxy)-ethylamino]]-3-[2-(indol-2-yl)-phenoxy]-2-propanol 
• 81015-32-9 1-[N-benzyl-2-(3-carbamoyl-4-hydroxyphenoxy)-ethylamino]-3-[4-(1-methyl-2-oxodihydropyridin-6-yl)-phenoxy]-2-propanol 
• 81127-97-1 1-[N-benzyl-[2-(3-carbamoyl-4-hydroxyphenoxy)-ethylamino]]-3-[4-(1-methyl-3-methylsulphonyl-1H-1,2,4-triazol-5-yl)-phenoxy]-2-propanol 
• 81015-25-0 1-[N-benzyl-[2-(3-carbamoyl-4-hydroxyphenoxy)-ethylamino]]-3-[4-(1-methyl-5-trifluoromethyl-1H-1,2,4-triazol-3-yl)-phenoxy]-2-propanol 
• 81015-24-9 1-[N-benzyl-[2-(3-carbamoyl-4-hydroxyphenoxy)-ethylamino]]-3-[4-(4-methyl-5-trifluoromethyl-4H-1,2,4-triazol-3-yl)-phenoxy]-2-propanol 
• 81015-20-5 1-[N-benzyl-2-(3-carbamoyl-4-hydroxyphenoxy)-ethylamino]-3-(4-biphenyloxy)-2-propanol 
• 89789-97-9 2-Hydroxy-5-{2-[2-hydroxy-6-(2-methoxy-phenyl)-hexylamino]-ethoxy}-benzamide 
• 84815-02-1 2-Hydroxy-5-{2-[2-hydroxy-5-(2-methoxy-phenyl)-pentylamino]-ethoxy}-benzamide 

Relevant academic research and scientific papers

β-Adrenergic blocking agents: Substituted phenylalkanolamines. Effect of side-chain length on β-blocking potency in vitro

The synthesis of a group of potential β-blockers bearing a new 5-ethoxysalicylamide substituent on nitrogen is described. These compounds were tested for β-adrenergic blocking potency in vitro and compared with analogous compounds bearing a tert-butyl group on nitrogen. The new N-substituent increased the β-blocking potency substantially. In a series of five homologous compounds of the type Ar(CH2)(n)CHOHCH2NHR (R = 5-ethoxysalicylamide; n = 0-4), two maxima of β-blocking potency were found for n = 0 and 2. Moreover, the carbon isostere of the corresponding (aryloxy)propanolamine still proved to be a very potent β-blocker. The ether oxygen in the side chain is therefore not an absolute requirement for activity. Structure-activity relationships are discussed.